scholarly journals Effect of diquafosol ophthalmic solution on the optical quality of the eyes in patients with aqueous-deficient dry eye

2014 ◽  
Vol 92 (8) ◽  
pp. e671-e675 ◽  
Author(s):  
Shizuka Koh ◽  
Naoyuki Maeda ◽  
Chikako Ikeda ◽  
Yoshinori Oie ◽  
Takeshi Soma ◽  
...  
Keyword(s):  
Dry Eye ◽  
Ophthalmic Solution ◽  
Optical Quality ◽  
Diquafosol Ophthalmic Solution

scholarly journals Effectiveness and Optical Quality of Topical 3.0% Diquafosol versus 0.05% Cyclosporine A in Dry Eye Patients following Cataract Surgery

2016 ◽  
Vol 2016 ◽  
pp. 1-7 ◽  
Author(s):  
Jang Hoon Lee ◽  
In Seok Song ◽  
Kyoung Lae Kim ◽  
Sam Young Yoon
Keyword(s):  
Cataract Surgery ◽  
Dry Eye ◽  
Cyclosporine A ◽  
Ocular Surface ◽  
Ophthalmic Solution ◽  
Optical Quality ◽  
Ocular Surface Disease Index ◽  
Staining Score ◽  
Surface Staining

Purpose.To evaluate the effectiveness and optical quality of 3.0% topical diquafosol versus 0.05% cyclosporine A in dry eye patients following cataract surgery.Methods.In total, 40 eyes of 40 patients newly diagnosed with dry eye syndrome 1 week after cataract surgery were randomized to receive either 3.0% diquafosol ophthalmic solution six times daily or 0.05% cyclosporine A twice daily for 3 months. Outcome measures were tear film break-up time (TBUT), results on Schirmer 1 test, ocular surface staining score, the ocular surface disease index (OSDI) score, and higher-order aberrations (HOAs). Measurements were taken at baseline and at 1, 2, and 3 months.Results.In the diquafosol group, TBUT showed higher outcomes than the cyclosporine A group at 1 and 3 months. Both groups showed increased scores on Schirmer 1 test. The ocular surface staining score decreased in all periods in both groups. Vertical coma and total HOAs decreased more in the cyclosporine A group than in the diquafosol group at 3 months.Conclusion.Both 3.0% diquafosol and 0.05% cyclosporine A were effective in treating dry eye after cataract surgery. Diquafosol was more effective in increasing the tear secretion, but cyclosporine A was more effective in improving optical aberrations.

Long-term results of treatment with diquafosol ophthalmic solution for aqueous-deficient dry eye

2013 ◽  
Vol 57 (5) ◽  
pp. 440-446 ◽  
Author(s):  
Shizuka Koh ◽  
Chikako Ikeda ◽  
Yoshihiro Takai ◽  
Hitoshi Watanabe ◽  
Naoyuki Maeda ◽  
...  
Keyword(s):  
Dry Eye ◽  
Ophthalmic Solution ◽  
Long Term Results ◽  
Results Of Treatment ◽  
Diquafosol Ophthalmic Solution

scholarly journals Patients Preference of Diquafosol or Rebamipide Eye Drops for the Treatment of Mild Dry Eye: A Pilot Study

2018 ◽  
Vol 1 (1) ◽  
pp. 39-45
Author(s):  
Maria Yamamoto ◽  
Yukihiro Horie ◽  
Yoshiaki Tagawa ◽  
Susumu Ishida ◽  
Nobuyoshi Kitaichi
Keyword(s):  
Dry Eye ◽  
Tear Film ◽  
Ophthalmic Solution ◽  
Signs And Symptoms ◽  
Eye Drops ◽  
Subjective Assessments ◽  
Significant Difference ◽  
Related Quality ◽  
Old Females

Purpose: To investigate the preference rates of recently developed eye drops, 3% diquafosol ophthalmic solution and 2% rebamipide ophthalmic suspension, as a randomized clinical trial in patients with dry eye.Methods: Eighteen patients (mean age: 59.7 years old, females: 77.8%) with reduced tear film break-up time (TBUT ? 5 sec) were enrolled in this study. They were treated with either diquafosol or rebamipide for 1 week, and treated for an additional week after switching to the other eye drop. This treatment was repeated one more time. Then, the patients were treated with one of either eye drop for an additional 4 weeks. Patients’ preferences for eye drops were investigated using a questionnaire at the end of 4-week treatment. To confirm the effectiveness of the treatments, objective and subjective assessments including superficial punctate keratopathy (SPK) score, TBUT measurement, and Dry Eye-Related Quality-of-Life Score (DEQS) were performed at baseline, and 4 and 8 weeks.Results: SPK score was improved after treatment (P < 0.05). Patients tended to prefer diquafosol (64.7%) torebamipide (35.4%), however there was no significant difference in two eye drops (P = 0.23). Bitterness was reported significantly more frequently after rebamipide administration (66.7%) than diquafosol administration (5.6%, P < 0.001). The diquafosol bottle was considered “ease to use” by a larger percentage of users (94.1%) as compared to the rebamipide bottle (58.8%, P < 0.05). The effectiveness of the signs and symptoms were similar for both groups at 8 weeks.Conclusions: Diquafosol and Rebamipide were both effective in treating dry eye and 65% of the patients choose Diquafosol. Bitterness after administration and ease to use of the bottles seemed to affect the patients’ preferences for these two eye drops.

scholarly journals Changes of Corneal Wavefront Aberrations in Dry Eye Patients after Treatment with Artificial Lubricant Drops

2016 ◽  
Vol 2016 ◽  
pp. 1-11 ◽  
Author(s):  
Ning Lu ◽  
Fangyu Lin ◽  
Zhu Huang ◽  
Qin He ◽  
Wei Han
Keyword(s):  
Dry Eye ◽  
Spherical Aberration ◽  
Optical Quality ◽  
Control Group ◽  
Eye Drops ◽  
Artificial Eye ◽  
Corneal Surface ◽  
Wavefront Aberrations ◽  
Corneal Aberrations

Purpose.To evaluate the corneal aberration changes in dry eye patients after treatment with artificial eye drops.Methods.Thirty mild to moderate dry eye patients treated with artificial eye drops and twenty comparable dry eye patients were recruited as controls. Anterior corneal aberrations over 3 mm and 5 mm analytical zones including total, 3rd to 5th high order aberrations (HOAs), spherical aberration (SA), and vertical (V-coma) and horizontal coma (H-coma) obtained from corneal topography data at baseline and 2 weeks after treatment were evaluated.Results.For 3 mm zone, trefoils, V-coma, H-coma terms, and 3rd and 5th HOAs were significantly decreased (p<0.05) in the treatment group. For 5 mm zone, instillation of eye drops reduced H-coma, SA terms, 3rd to 5th orders, and total HOAs all showed a significant decrease (p<0.05). The root mean square analysis of the Zernike terms also showed similar statistical results. For control group, all individual terms and total HOAs did not have significant changes over 3 mm and 5 mm zones (p>0.05).Conclusions.Treatment with artificial eye drops can effectively improve the corneal optical quality of dry eye patients by ameliorating the HOAs of anterior corneal surface.

scholarly journals Clinical effectiveness of diquafosol ophthalmic solution 3% in Korean patients with dry eye disease: a multicenter prospective observational study

2021 ◽  
Vol 14 (10) ◽  
pp. 1518-1526
Author(s):  
Youngsub Eom ◽  
Keyword(s):  
Dry Eye ◽  
Ophthalmic Solution ◽  
Dry Eye Disease ◽  
Eye Disease ◽  
Dependent Manner ◽  
Subjective Symptoms ◽  
Korean Patients ◽  
Staining Score ◽  
Switch Group ◽  
Diquafosol Ophthalmic Solution

AIM: To investigate the effectiveness of diquafosol ophthalmic solution 3% administered in Korean patients with dry eye disease in real-world clinical settings. METHODS: Diquafosol was administered for 8wk to 3 patient groups who received diquafosol as add-on therapy to existing medication (Add group, n=150); received diquafosol only (Monotherapy group, n=196); or discontinued part of their existing medication in favor of diquafosol (Switch group, n=11). Tear break-up time (TBUT), cornea and conjunctival staining based on National Eye Institute/Industry scoring scheme, subjective symptoms using the Ocular Surface Disease Index (OSDI) questionnaire, and meibum quality and expressibility were evaluated at baseline, week 4, and week 8. RESULTS: The mean TBUT increased (from 3.46, 3.92, and 5.84s, respectively, to 5.15, 5.53, and 8.59s, respectively) and corneal staining score decreased (from 2.23, 2.24, and 3.09, respectively, to 0.85, 0.97, and 1.64, respectively) in a time-dependent manner from baseline to week 8 in all three groups. Conjunctival staining score, OSDI questionnaire, and meibum quality and expressibility improved over time from baseline to week 8 in the Add and Monotherapy groups, but differences were not statistically significant in the Switch group. CONCLUSION: Diquafosol improves subjective symptoms and objective signs in patients treated with existing medicines combined with diquafosol and treated solely with diquafosol. Diquafosol can be used as an effective therapeutic agent for dry eye disease or additionally applied in patients who have insufficient response to existing medicines.

Sign in / Sign up

Export Citation Format

Share Document